CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Vaderis hauls in $152M to test an AKT-targeting drug

Positive
AI Analysis

Summary

Vaderis raised $152M in funding to develop an AKT-targeting drug for hereditary hemorrhagic telangiectasia, a rare bleeding disorder. The company is among several biotech firms pursuing more precise AKT inhibitors for this indication.

Importance:6/10
Sentiment:
0.60
fundingAKT inhibitorhereditary hemorrhagic telangiectasiarare disease

Read the original article

Published by BioPharma Dive on August 11, 2026 11:00 AM

Read Original